Advertisement

High-Risk Asthma Clinic: Putting It All Together

  • Navitha Ramesh
  • Fernando Holguin
  • Sandhya KhuranaEmail author
Chapter
Part of the Respiratory Medicine book series (RM)

Abstract

Severe asthma makes up for less than 10% of all asthma but is associated with disproportionately high healthcare costs. In 2019, asthma is not a one-size-fits-all disease. Heterogeneity in asthma is becoming increasingly evident. Not every patient with severe asthma has the same underlying pathophysiology or responds in a similar manner to targeted therapy. Keeping this in mind, a multidimensional and interdisciplinary approach to the management of severe asthma is desired. The role of patient-care teams in management of chronic diseases has become increasingly accepted, and this is particularly true for difficult or severe asthma. A high-risk asthma service can provide patients with state-of-the-art, evidence-based clinical management. This chapter provides an overview of complexities of “difficult-to-control” asthma and a practical systematic approach to its management.

Keywords

High-risk asthma clinic Severe asthma Difficult asthma Severe asthma clinic Structured evaluation Multidisciplinary 

References

  1. 1.
    Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald JM, Gibson P, Ohta K, O’Byrne P, Pedersen SE, Pizzichini E, Sullivan SD, Wenzel SE, Zar HJ. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–78. 2018;51(2):2007. Print 18 Feb.CrossRefGoogle Scholar
  2. 2.
    GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.CrossRefGoogle Scholar
  3. 3.
    Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.CrossRefGoogle Scholar
  4. 4.
    Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J, et al. Economic burden of asthma: a systematic review. BMC Pulm Med. 2009;9:24.CrossRefGoogle Scholar
  5. 5.
    Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res. 2018;4(1)CrossRefGoogle Scholar
  6. 6.
    Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22–37.CrossRefGoogle Scholar
  7. 7.
    Holgate ST. Innate and adaptive immune responses in asthma. Nat Med. 2012;18(5):673–83.CrossRefGoogle Scholar
  8. 8.
    Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66(10):910–7.CrossRefGoogle Scholar
  9. 9.
    Wagner EH. The role of patient care teams in chronic disease management. BMJ. 2000;320(7234):569–72.CrossRefGoogle Scholar
  10. 10.
    Gibeon D, Heaney LG, Brightling CE, Niven R, Mansur AH, Chaudhuri R, et al. Dedicated severe asthma services improve health-care use and quality of life. Chest. 2015;148(4):870–6.CrossRefGoogle Scholar
  11. 11.
    Tay TR, Lee J, Radhakrishna N, Hore-Lacy F, Stirling R, Hoy R, et al. A structured approach to specialist-referred difficult asthma patients improves control of comorbidities and enhances asthma outcomes. J Allergy Clin Immunol Pract. 2017;5(4):956–64 e3.CrossRefGoogle Scholar
  12. 12.
    Radhakrishna N, Tay TR, Hore-Lacy F, Stirling R, Hoy R, Dabscheck E, et al. Validated questionnaires heighten detection of difficult asthma comorbidities. J Asthma. 2017;54(3):294–9.CrossRefGoogle Scholar
  13. 13.
    van der Meer AN, Pasma H, Kempenaar-Okkema W, Pelinck JA, Schutten M, Storm H, et al. A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use. Eur Respir J. 2016;48(3):726–33.CrossRefGoogle Scholar
  14. 14.
    Brozek GM, Farnik M, Lawson J, Zejda JE. Underdiagnosis of childhood asthma: a comparison of survey estimates to clinical evaluation. Int J Occup Med Environ Health. 2013;26(6):900–9.CrossRefGoogle Scholar
  15. 15.
    Enright PL, McClelland RL, Newman AB, Gottlieb DJ, Lebowitz MD. Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest. 1999;116(3):603–13.CrossRefGoogle Scholar
  16. 16.
    José BP, Camargos PA, Cruz Filho Á, ReA C. Diagnostic accuracy of respiratory diseases in primary health units. Rev Assoc Med Bras (1992). 2014;60(6):599–612.CrossRefGoogle Scholar
  17. 17.
    van Huisstede A, Castro Cabezas M, van de Geijn GJ, Mannaerts GH, Njo TL, Taube C, et al. Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respir Med. 2013;107(9):1356–64.CrossRefGoogle Scholar
  18. 18.
    Nathell L, Larsson K, Jensen I. Determinants of undiagnosed asthma. Allergy. 2002;57(8):687–93.CrossRefGoogle Scholar
  19. 19.
    Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemiere C, et al. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317(3):269–79.CrossRefGoogle Scholar
  20. 20.
    Irwin RS, Curley FJ, French CL. Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol. Chest. 1993;103(6):1662–9.CrossRefGoogle Scholar
  21. 21.
    Heaney LG, Conway E, Kelly C, Johnston BT, English C, Stevenson M, et al. Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol. Thorax. 2003;58(7):561–6.CrossRefGoogle Scholar
  22. 22.
    Hekking PP, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.CrossRefGoogle Scholar
  23. 23.
    Kogevinas M, Zock JP, Jarvis D, Kromhout H, Lillienberg L, Plana E, et al. Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II). Lancet. 2007;370(9584):336–41.CrossRefGoogle Scholar
  24. 24.
    Luskin AT, Chipps BE, Rasouliyan L, Miller DP, Haselkorn T, Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544–52.e1-2.CrossRefGoogle Scholar
  25. 25.
    Phipatanakul W, Matsui E, Portnoy J, Williams PB, Barnes C, Kennedy K, et al. Environmental assessment and exposure reduction of rodents: a practice parameter. Ann Allergy Asthma Immunol. 2012;109(6):375–87.CrossRefGoogle Scholar
  26. 26.
    Portnoy J, Kennedy K, Sublett J, Phipatanakul W, Matsui E, Barnes C, et al. Environmental assessment and exposure control: a practice parameter–furry animals. Ann Allergy Asthma Immunol. 2012;108(4):223.e1–15.CrossRefGoogle Scholar
  27. 27.
    Portnoy J, Miller JD, Williams PB, Chew GL, Zaitoun F, Phipatanakul W, et al. Environmental assessment and exposure control of dust mites: a practice parameter. Ann Allergy Asthma Immunol. 2013;111(6):465–507.CrossRefGoogle Scholar
  28. 28.
    Portnoy J, Chew GL, Phipatanakul W, Williams PB, Grimes C, Kennedy K, et al. Environmental assessment and exposure reduction of cockroaches: a practice parameter. J Allergy Clin Immunol. 2013;132(4):802–8.e1-25.CrossRefGoogle Scholar
  29. 29.
    Matsui EC, Perzanowski M, Peng RD, Wise RA, Balcer-Whaley S, Newman M, et al. Effect of an integrated pest management intervention on asthma symptoms among mouse-sensitized children and adolescents with asthma: a randomized clinical trial. JAMA. 2017;317(10):1027–36.CrossRefGoogle Scholar
  30. 30.
    Bresciani M, Paradis L, Des Roches A, Vernhet H, Vachier I, Godard P, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol. 2001;107(1):73–80.CrossRefGoogle Scholar
  31. 31.
    Heaney LG, Conway E, Kelly C, Gamble J. Prevalence of psychiatric morbidity in a difficult asthma population: relationship to asthma outcome. Respir Med. 2005;99(9):1152–9.CrossRefGoogle Scholar
  32. 32.
    Julien JY, Martin JG, Ernst P, Olivenstein R, Hamid Q, Lemière C, et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol. 2009;124(2):371–6.CrossRefGoogle Scholar
  33. 33.
    Leggett JJ, Johnston BT, Mills M, Gamble J, Heaney LG. Prevalence of gastroesophageal reflux in difficult asthma: relationship to asthma outcome. Chest. 2005;127(4):1227–31.PubMedGoogle Scholar
  34. 34.
    Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology. 2017;22(7):1262–75.CrossRefGoogle Scholar
  35. 35.
    Tay TR, Radhakrishna N, Hore-Lacy F, Smith C, Hoy R, Dabscheck E, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384–90.CrossRefGoogle Scholar
  36. 36.
    Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33(4):897–906.CrossRefGoogle Scholar
  37. 37.
    Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180(9):817–22.CrossRefGoogle Scholar
  38. 38.
    Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P, et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012;67(8):751–3.CrossRefGoogle Scholar
  39. 39.
    Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45(2):396–407.CrossRefGoogle Scholar
  40. 40.
    Lee J, Tay TR, Radhakrishna N, Hore-Lacy F, Mackay A, Hoy R, et al. Nonadherence in the era of severe asthma biologics and thermoplasty. Eur Respir J. 2018;51(4):1701836.CrossRefGoogle Scholar
  41. 41.
    Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. Arch Intern Med. 2006;166(17):1855–62.CrossRefGoogle Scholar
  42. 42.
    van Boven JFM, Lavorini F, Dekhuijzen PNR, Blasi F, Price DB, Viegi G. Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy. Eur Respir J. 2017;49(5):1700076.CrossRefGoogle Scholar
  43. 43.
    Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin N Am. 2005;25(1):107–30.CrossRefGoogle Scholar
  44. 44.
    Krishnan JA, Bender BG, Wamboldt FS, Szefler SJ, Adkinson NF, Zeiger RS, et al. Adherence to inhaled corticosteroids: an ancillary study of the childhood asthma management program clinical trial. J Allergy Clin Immunol. 2012;129(1):112–8.CrossRefGoogle Scholar
  45. 45.
    Gamble J, Stevenson M, Heaney LG. A study of a multi-level intervention to improve non-adherence in difficult to control asthma. Respir Med. 2011;105(9):1308–15.CrossRefGoogle Scholar
  46. 46.
    Al-Jahdali H, Ahmed A, Al-Harbi A, Khan M, Baharoon S, Bin Salih S, et al. Improper inhaler technique is associated with poor asthma control and frequent emergency department visits. Allergy Asthma Clin Immunol. 2013;9(1):8.CrossRefGoogle Scholar
  47. 47.
    Sanchis J, Gich I, Pedersen S, (ADMIT) ADMIT. Systematic review of errors in inhaler use: has patient technique improved over time? Chest. 2016;150(2):394–406.CrossRefGoogle Scholar
  48. 48.
    Hardwell A, Barber V, Hargadon T, McKnight E, Holmes J, Levy ML. Technique training does not improve the ability of most patients to use pressurised metered-dose inhalers (pMDIs). Prim Care Respir J. 2011;20(1):92–6.CrossRefGoogle Scholar
  49. 49.
    Kew KM, Malik P, Aniruddhan K, Normansell R. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017;(10):CD012330.Google Scholar
  50. 50.
    Pinnock H, Parke HL, Panagioti M, Daines L, Pearce G, Epiphaniou E, et al. Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Med. 2017;15(1):64.CrossRefGoogle Scholar
  51. 51.
    Gibson PG, Powell H, Coughlan J, Wilson AJ, Abramson M, Haywood P, et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;(1):CD001117.Google Scholar
  52. 52.
    Gibson PG, Powell H, Wilson A, Abramson MJ, Haywood P, Bauman A, Hensley MJ, Walters EH, Roberts JJL. Self‐management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2002;(3):CD001117.  https://doi.org/10.1002/14651858.CD001117.
  53. 53.
    Gupta S, Kaplan A. Solving the mystery of the yellow zone of the asthma action plan. NPJ Prim Care Respir Med. 2018;28(1):1.CrossRefGoogle Scholar
  54. 54.
    Ring N, Jepson R, Hoskins G, Wilson C, Pinnock H, Sheikh A, et al. Understanding what helps or hinders asthma action plan use: a systematic review and synthesis of the qualitative literature. Patient Educ Couns. 2011;85(2):e131–43.CrossRefGoogle Scholar
  55. 55.
    Cingi C, Yorgancioglu A, Cingi CC, Oguzulgen K, Muluk NB, Ulusoy S, et al. The “physician on call patient engagement trial” (POPET): measuring the impact of a mobile patient engagement application on health outcomes and quality of life in allergic rhinitis and asthma patients. Int Forum Allergy Rhinol. 2015;5(6):487–97.CrossRefGoogle Scholar
  56. 56.
    Miller L, Schüz B, Walters J, Walters EH. Mobile technology interventions for asthma self-management: systematic review and meta-analysis. JMIR Mhealth Uhealth. 2017;5(5):e57.CrossRefGoogle Scholar
  57. 57.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97.CrossRefGoogle Scholar
  58. 58.
    Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–58.CrossRefGoogle Scholar
  59. 59.
    Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85.CrossRefGoogle Scholar
  60. 60.
    Chipps BE, Corren J, Israel E, Katial R, Lang DM, Panettieri RA Jr, et al. Asthma yardstick: practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma. Ann Allergy Asthma Immunol. 2017;118(2):133–42 e3.CrossRefGoogle Scholar
  61. 61.
    Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178(3):218–24.CrossRefGoogle Scholar
  62. 62.
    Moore WC, Meyers DA, Wenzel SE, Teague WG, Li H, Li X, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–23.CrossRefGoogle Scholar
  63. 63.
    Siroux V, Basagaña X, Boudier A, Pin I, Garcia-Aymerich J, Vesin A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J. 2011;38(2):310–7.CrossRefGoogle Scholar
  64. 64.
    Cabana MD, Slish KK, Evans D, Mellins RB, Brown RW, Lin X, et al. Impact of Physician Asthma Care Education on patient outcomes. Health Educ Behav. 2014;41(5):509–17.CrossRefGoogle Scholar
  65. 65.
    Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther. 2014;27(2):129–38.CrossRefGoogle Scholar
  66. 66.
    ten Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinderman AH, et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J. 2005;26(5):812–8.CrossRefGoogle Scholar
  67. 67.
    Bousquet J, Brusselle G, Buhl R, Busse WW, Cruz AA, Djukanovic R, et al. Care pathways for the selection of a biologic in severe asthma. Eur Respir J. 2017;50(6):1701782.CrossRefGoogle Scholar
  68. 68.
    Worth A, Hammersley V, Knibb R, Flokstra-de-Blok B, DunnGalvin A, Walker S, et al. Patient-reported outcome measures for asthma: a systematic review. NPJ Prim Care Respir Med. 2014;24:14020.CrossRefGoogle Scholar
  69. 69.
    McDonald VM, Maltby S, Reddel HK, King GG, Wark PA, Smith L, et al. Severe asthma: current management, targeted therapies and future directions-A roundtable report. Respirology. 2017;22(1):53–60.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Navitha Ramesh
    • 1
    • 2
  • Fernando Holguin
    • 3
  • Sandhya Khurana
    • 4
    Email author
  1. 1.Geisinger Commonwealth School of MedicineScrantonUSA
  2. 2.Geisinger Wyoming Valley Medical CenterWilkes-BarreUSA
  3. 3.Asthma Clinical & Research Programs, Pulmonary Sciences and Critical CareUniversity of ColoradoDenverUSA
  4. 4.Mary Parkes Center for Asthma, Allergy & Pulmonary Care, University of Rochester School of MedicineRochesterUSA

Personalised recommendations